Compared with the derivation cohort, patients in the validation cohort had higher LVEF and lower GRACE score, a lower prevalence of diabetes mellitus and three-vessel disease, and less frequent use of intra-aortic balloon pump, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and beta-blockers. Here, ACE is linked to diabetes mellitus.